Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/AKR1C1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/AKR1C1_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/AKR1C1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/AKR1C1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/AKR1C1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/AKR1C1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00705421 | Stomach | CAG with IM | response to fatty acid | 10/1050 | 64/18723 | 2.82e-03 | 2.69e-02 | 10 |
GO:00421801 | Stomach | CAG with IM | cellular ketone metabolic process | 22/1050 | 211/18723 | 3.81e-03 | 3.35e-02 | 22 |
GO:00988561 | Stomach | CAG with IM | intestinal lipid absorption | 5/1050 | 21/18723 | 5.26e-03 | 4.19e-02 | 5 |
GO:1902644 | Stomach | CAG with IM | tertiary alcohol metabolic process | 5/1050 | 21/18723 | 5.26e-03 | 4.19e-02 | 5 |
GO:00424451 | Stomach | CAG with IM | hormone metabolic process | 22/1050 | 218/18723 | 5.61e-03 | 4.40e-02 | 22 |
GO:000608111 | Stomach | CAG with IM | cellular aldehyde metabolic process | 9/1050 | 60/18723 | 5.94e-03 | 4.61e-02 | 9 |
GO:00075862 | Stomach | CSG | digestion | 25/1034 | 137/18723 | 1.15e-07 | 8.25e-06 | 25 |
GO:00335592 | Stomach | CSG | unsaturated fatty acid metabolic process | 22/1034 | 116/18723 | 3.28e-07 | 2.02e-05 | 22 |
GO:000941021 | Stomach | CSG | response to xenobiotic stimulus | 53/1034 | 462/18723 | 3.69e-07 | 2.22e-05 | 53 |
GO:00066922 | Stomach | CSG | prostanoid metabolic process | 13/1034 | 49/18723 | 1.69e-06 | 7.96e-05 | 13 |
GO:00066932 | Stomach | CSG | prostaglandin metabolic process | 13/1034 | 49/18723 | 1.69e-06 | 7.96e-05 | 13 |
GO:007259321 | Stomach | CSG | reactive oxygen species metabolic process | 32/1034 | 239/18723 | 3.18e-06 | 1.37e-04 | 32 |
GO:00066902 | Stomach | CSG | icosanoid metabolic process | 21/1034 | 123/18723 | 3.57e-06 | 1.51e-04 | 21 |
GO:000663121 | Stomach | CSG | fatty acid metabolic process | 43/1034 | 390/18723 | 1.25e-05 | 4.20e-04 | 43 |
GO:002260021 | Stomach | CSG | digestive system process | 18/1034 | 104/18723 | 1.44e-05 | 4.63e-04 | 18 |
GO:200037921 | Stomach | CSG | positive regulation of reactive oxygen species metabolic process | 14/1034 | 76/18723 | 6.23e-05 | 1.55e-03 | 14 |
GO:01202542 | Stomach | CSG | olefinic compound metabolic process | 20/1034 | 153/18723 | 2.95e-04 | 5.09e-03 | 20 |
GO:00466832 | Stomach | CSG | response to organophosphorus | 17/1034 | 131/18723 | 8.87e-04 | 1.18e-02 | 17 |
GO:00713982 | Stomach | CSG | cellular response to fatty acid | 8/1034 | 38/18723 | 9.35e-04 | 1.22e-02 | 8 |
GO:200037721 | Stomach | CSG | regulation of reactive oxygen species metabolic process | 19/1034 | 157/18723 | 1.08e-03 | 1.35e-02 | 19 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0520839 | Esophagus | HGIN | Chemical carcinogenesis - reactive oxygen species | 92/1383 | 223/8465 | 2.41e-19 | 9.83e-18 | 7.80e-18 | 92 |
hsa05208115 | Esophagus | HGIN | Chemical carcinogenesis - reactive oxygen species | 92/1383 | 223/8465 | 2.41e-19 | 9.83e-18 | 7.80e-18 | 92 |
hsa05208211 | Esophagus | ESCC | Chemical carcinogenesis - reactive oxygen species | 168/4205 | 223/8465 | 1.83e-15 | 6.81e-14 | 3.49e-14 | 168 |
hsa05208310 | Esophagus | ESCC | Chemical carcinogenesis - reactive oxygen species | 168/4205 | 223/8465 | 1.83e-15 | 6.81e-14 | 3.49e-14 | 168 |
hsa0520814 | Liver | NAFLD | Chemical carcinogenesis - reactive oxygen species | 44/1043 | 223/8465 | 9.22e-04 | 1.31e-02 | 1.06e-02 | 44 |
hsa0520815 | Liver | NAFLD | Chemical carcinogenesis - reactive oxygen species | 44/1043 | 223/8465 | 9.22e-04 | 1.31e-02 | 1.06e-02 | 44 |
hsa0520822 | Liver | Cirrhotic | Chemical carcinogenesis - reactive oxygen species | 121/2530 | 223/8465 | 1.35e-14 | 4.08e-13 | 2.52e-13 | 121 |
hsa0520832 | Liver | Cirrhotic | Chemical carcinogenesis - reactive oxygen species | 121/2530 | 223/8465 | 1.35e-14 | 4.08e-13 | 2.52e-13 | 121 |
hsa0520862 | Liver | Cyst | Chemical carcinogenesis - reactive oxygen species | 40/339 | 223/8465 | 4.80e-16 | 3.45e-14 | 2.85e-14 | 40 |
hsa0520872 | Liver | Cyst | Chemical carcinogenesis - reactive oxygen species | 40/339 | 223/8465 | 4.80e-16 | 3.45e-14 | 2.85e-14 | 40 |
hsa0520830 | Oral cavity | OSCC | Chemical carcinogenesis - reactive oxygen species | 150/3704 | 223/8465 | 6.45e-13 | 1.20e-11 | 6.11e-12 | 150 |
hsa05208114 | Oral cavity | OSCC | Chemical carcinogenesis - reactive oxygen species | 150/3704 | 223/8465 | 6.45e-13 | 1.20e-11 | 6.11e-12 | 150 |
hsa05208210 | Oral cavity | LP | Chemical carcinogenesis - reactive oxygen species | 119/2418 | 223/8465 | 3.00e-15 | 8.32e-14 | 5.37e-14 | 119 |
hsa0520838 | Oral cavity | LP | Chemical carcinogenesis - reactive oxygen species | 119/2418 | 223/8465 | 3.00e-15 | 8.32e-14 | 5.37e-14 | 119 |
hsa0520812 | Stomach | GC | Chemical carcinogenesis - reactive oxygen species | 65/708 | 223/8465 | 3.46e-20 | 2.72e-18 | 1.91e-18 | 65 |
hsa00980 | Stomach | GC | Metabolism of xenobiotics by cytochrome P450 | 15/708 | 78/8465 | 1.77e-03 | 1.16e-02 | 8.15e-03 | 15 |
hsa0520813 | Stomach | GC | Chemical carcinogenesis - reactive oxygen species | 65/708 | 223/8465 | 3.46e-20 | 2.72e-18 | 1.91e-18 | 65 |
hsa009801 | Stomach | GC | Metabolism of xenobiotics by cytochrome P450 | 15/708 | 78/8465 | 1.77e-03 | 1.16e-02 | 8.15e-03 | 15 |
hsa0520821 | Stomach | CAG with IM | Chemical carcinogenesis - reactive oxygen species | 65/640 | 223/8465 | 1.37e-22 | 1.09e-20 | 7.65e-21 | 65 |
hsa0520831 | Stomach | CAG with IM | Chemical carcinogenesis - reactive oxygen species | 65/640 | 223/8465 | 1.37e-22 | 1.09e-20 | 7.65e-21 | 65 |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1645 | AKR1C1 | DRUGGABLE GENOME, ENZYME | | 2-(4-CHLOROBENZYLIDENE)CYCLOPENTANONE | CHEMBL562352 | 19237229 |
1645 | AKR1C1 | DRUGGABLE GENOME, ENZYME | | HUMAN CHORIONIC GONADOTROPIN | | 436730 |
1645 | AKR1C1 | DRUGGABLE GENOME, ENZYME | | ESTRONE | ESTRONE | 3859707 |
1645 | AKR1C1 | DRUGGABLE GENOME, ENZYME | | 3,5-DIBROMOSALICYLIC ACID | CHEMBL447448 | 19397269 |
1645 | AKR1C1 | DRUGGABLE GENOME, ENZYME | | 3,5-DICHLOROSALICYLIC ACID | CHEMBL449129 | 21414777 |
1645 | AKR1C1 | DRUGGABLE GENOME, ENZYME | | PROGESTERONE | PROGESTERONE | 6584862,12604236,3463506,2547059,6950669,3859707,179793,6288675 |